

Special Issue

Thrombocythemia: Current Status, Challenges and Future Directions

Message from the Guest Editor

Essential Thrombocythemia (ET) is characterized by abnormal megakaryocytes and thrombocytosis. The ET is generally associated with mutations such as JAK2 exon 14, CALR exon 9, or MPL exon 10 (W515R/G/S). However, about 10% of patients with ET are triple negative (TN). TN patients can have “noncanonical” MPL mutations (T119I, S204F/P, E230G, Y252H and Y591D/N, R537W (exon 11), P453R and S505N (exon 9)). In addition, ET patient genes of platelet proliferation (ITGA2B and ITGB3) and DNA methylation profiles can characterize the ET and represent potential novel mechanisms of disease initiation. Thrombosis and myelofibrosis progression are a leading cause of morbidity and mortality in ET. ET is managed with aspirin and selected use of hydroxycarbamide (HC), interferon γ (IFN γ), or anagrelide. However, therapy remains suboptimal with the ongoing risk for thrombosis and risk for transformation. An emerging therapy is represented by the JAK inhibitor (ruxolitinib).

Guest Editor

Dr. Emma C. Cacciola

Hemostasis Unit, Department of Medical, Surgical Sciences and Advanced Technologies “G.F. Ingrassia”, University of Catania, Catania, Italy

Deadline for manuscript submissions

closed (15 December 2022)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/101478

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).